- Home
- ITW vs EXEL Comparison
ITW vs EXEL Comparison
Compare ITW & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITW
- EXEL
- Stock Information
- Founded
- ITW 1912
- EXEL 1994
- Country
- ITW United States
- EXEL United States
- Employees
- ITW N/A
- EXEL N/A
- Industry
- ITW Industrial Machinery/Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ITW Industrials
- EXEL Health Care
- Exchange
- ITW Nasdaq
- EXEL Nasdaq
- Market Cap
- ITW 67.7B
- EXEL 9.8B
- IPO Year
- ITW N/A
- EXEL 2000
- Fundamental
- Price
- ITW $241.78
- EXEL $38.55
- Analyst Decision
- ITW Hold
- EXEL Buy
- Analyst Count
- ITW 10
- EXEL 18
- Target Price
- ITW $260.40
- EXEL $37.59
- AVG Volume (30 Days)
- ITW 1.3M
- EXEL 2.4M
- Earning Date
- ITW 04-30-2025
- EXEL 05-09-2025
- Dividend Yield
- ITW 2.50%
- EXEL N/A
- EPS Growth
- ITW 20.23
- EXEL 170.77
- EPS
- ITW 11.71
- EXEL 1.76
- Revenue
- ITW $15,898,000,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- ITW N/A
- EXEL $5.78
- Revenue Next Year
- ITW $3.15
- EXEL $10.94
- P/E Ratio
- ITW $20.45
- EXEL $21.91
- Revenue Growth
- ITW N/A
- EXEL 18.50
- 52 Week Low
- ITW $214.66
- EXEL $20.14
- 52 Week High
- ITW $279.13
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- ITW 51.93
- EXEL 63.64
- Support Level
- ITW $224.90
- EXEL $35.34
- Resistance Level
- ITW $243.46
- EXEL $37.67
- Average True Range (ATR)
- ITW 6.91
- EXEL 1.17
- MACD
- ITW 2.12
- EXEL 0.34
- Stochastic Oscillator
- ITW 91.23
- EXEL 96.71
About ITW Illinois Tool Works Inc.
Founded in 1912, Illinois Tool Works has become a diversified industrial manufacturer through acquisitions and innovations that follow customer needs. ITW operates through seven business segments, with no segment representing more than one fifth of revenue. ITW's automotive OEM segment sells vehicle components; its food equipment segment sells commercial kitchen appliances; its test & measurement and electronics segment sells inspection and analysis equipment; its welding segment sells welding equipment and consumables; its polymers & fluids segment sells industrial and consumer adhesives, solvents, and coatings; its construction products segment sells building fasteners and tools; and its specialty products segment sells medical, packaging, HVAC, and airport ground equipment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.